Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Average Rating of “Hold” by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been given an average rating of “Hold” by the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $5.8333.

A number of equities research analysts have recently issued reports on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Tuesday, April 7th. Wells Fargo & Company assumed coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price objective on the stock. Guggenheim raised their target price on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, April 10th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a report on Friday, May 22nd.

Institutional Trading of Zentalis Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. 5AM Venture Management LLC increased its holdings in shares of Zentalis Pharmaceuticals by 705.7% during the 4th quarter. 5AM Venture Management LLC now owns 3,947,913 shares of the company’s stock worth $5,330,000 after buying an additional 3,457,913 shares during the last quarter. Millennium Management LLC grew its position in Zentalis Pharmaceuticals by 220.6% in the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company’s stock worth $4,881,000 after acquiring an additional 2,111,951 shares during the period. Vanguard Group Inc. grew its position in Zentalis Pharmaceuticals by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,904,400 shares of the company’s stock worth $4,386,000 after acquiring an additional 19,768 shares during the period. Renaissance Technologies LLC increased its stake in Zentalis Pharmaceuticals by 24.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,883,745 shares of the company’s stock worth $3,893,000 after acquiring an additional 558,390 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in Zentalis Pharmaceuticals by 117.1% during the third quarter. Bank of America Corp DE now owns 1,548,781 shares of the company’s stock worth $2,339,000 after acquiring an additional 835,466 shares during the last quarter.

Zentalis Pharmaceuticals Trading Down 10.1%

NASDAQ:ZNTL opened at $4.36 on Friday. The company has a market cap of $310.39 million, a P/E ratio of -2.52 and a beta of 1.92. Zentalis Pharmaceuticals has a twelve month low of $1.15 and a twelve month high of $6.95. The company’s 50-day moving average price is $3.95 and its 200-day moving average price is $3.08.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, May 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.01). On average, analysts expect that Zentalis Pharmaceuticals will post -1.92 earnings per share for the current year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.